Revvity (RVTY) FY2024 10-K Annual Report
Revvity (RVTY) 10-K annual report for fiscal year 2024, filed with SEC EDGAR on Feb 25, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Revvity FY2024 10-K Analysis
Business Overview
- • Core business model: health science solutions delivering end-to-end workflows from discovery to diagnosis across Life Sciences and Diagnostics segments
- • New products FY 2024: BioLegend's TotalSeq™ PhenoCyte™ for scalable single-cell protein analysis; Cellometer™ Ascend automated cell counter; Phenologic.AI™ deep-learning software module
- • Strategic emphasis on broadening product portfolio via internal R&D and acquisitions, with focus on translational multi-omics, gene therapy reagents, and diagnostic genomics
- • Employee count approx. 11,000 as of Dec 29, 2024; global market reach in 160+ countries; S&P 500 component under ticker "RVTY"
- • Noteworthy diagnostic innovation: Ultrarapid Whole Genome Sequencing test delivering NICU results in as fast as five days
Management Discussion & Analysis
- • Revenue and profitability details not disclosed in provided section
- • No segment performance metrics available in provided text
- • Cash flow, capital allocation figures including buybacks, dividends, capex not stated
- • Forward-looking statements caution with no specific guidance or emerging risks detailed
Risk Factors
- • IRS audit and uncertain tax positions in foreign jurisdictions, with a $33.2 million increase in tax reserves in 2023
- • Ongoing foreign exchange risk, including a $24.0 million loss in 2023 cash proceeds held offshore
- • Supply chain and product mix shifts causing 16 basis point gross margin decline and $6.5 million higher cost of revenue in 2024
- • Market share pressure from applied genomics segment revenue decline by $23.7 million in 2024 despite growth in immunodiagnostics
- • Debt repayment risk from $711.5 million senior unsecured notes paid in 2024, with $1.5 billion revolving credit facility renewal through 2030
Revvity FY2024 Key Financial MetricsXBRL
Revenue
$2.8B
▲ +0.2% YoY
Net Income
$270M
▼ -61.0% YoY
Operating Margin
12.6%
▲ +166bp YoY
Net Margin
9.8%
▼ -1538bp YoY
ROE
3.5%
▼ -528bp YoY
Total Assets
$12.4B
▼ -8.6% YoY
EPS (Diluted)
$2.20
▼ -60.4% YoY
Operating Cash Flow
$628M
▲ +588.4% YoY
Source: XBRL data from Revvity FY2024 10-K filing on SEC EDGAR. All figures in USD.
Other Revvity Annual Reports
Get deeper insights on Revvity
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.